Literature DB >> 33323511

H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.

Juan Manuel Carreño1, Shirin Strohmeier1,2, Ericka Kirkpatrick Roubidoux1,3, Rong Hai4, Peter Palese1,5, Florian Krammer6.   

Abstract

Influenza virus infections leave a signature of immune memory that influences future responses to infections with antigenically related strains. It has been hypothesized that the first exposure in life to H1N1 influenza virus imprints the host immune system, potentially resulting in protection from severe infection with H5N1 later in life through hemagglutinin (HA) stalk-specific antibodies. To study the specific role of the HA on protection against infection without interference of cellular immunity or humoral antineuraminidase immunity, we primed mice with influenza B viruses that express an H1 HA (group 1; B-H1), H3 HA (group 2; B-H3), or wild-type influenza B virus and subsequently challenged them at different time points with an H5N1 virus. Weight loss and survival monitoring showed that the B-H1-primed mice exhibited better protection against H5N1 compared to the control mice. Analysis of H5-specific serum IgG, before and 21 days after H5N1 challenge, evidenced the presence of anti-stalk H5 cross-reactive antibodies in the BH-1 group that were boosted by H5N1 infection. The increased immune responses and protection induced by priming with the B-H1 viruses lasted at least up to 1 year. Hence, a single HA priming based on natural infection induces long-lasting protective immunity against heterosubtypic strains from the same phylogenetic HA group in mice. This study gives mechanistic support to the earlier finding in humans that imprinting by H1 HA protects against H5N1 infections and that highly conserved regions on the HA, like the stalk, are involved in this phenomenon.IMPORTANCE Current studies point out that an HA-mediated immunological imprint is established early in life during the first exposure to influenza viruses, which critically shapes and biases future immune responses. However, studies in animal models are limited and the precise mechanisms of this phenomenon are under investigation. Studies that explore the effect of HA-specific immunity induced during natural infection on future exposures to heterosubtypic influenza strains are needed.
Copyright © 2020 Carreño et al.

Entities:  

Keywords:  heterosubtypic immunity; imprinting; influenza; stalk antibodies

Year:  2020        PMID: 33323511      PMCID: PMC7773984          DOI: 10.1128/mBio.02090-20

Source DB:  PubMed          Journal:  mBio            Impact factor:   7.867


  52 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

3.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

4.  Cellular immune correlates of protection against symptomatic pandemic influenza.

Authors:  Saranya Sridhar; Shaima Begom; Alison Bermingham; Katja Hoschler; Walt Adamson; William Carman; Thomas Bean; Wendy Barclay; Jonathan J Deeks; Ajit Lalvani
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

5.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

6.  Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Authors:  Rong Hai; Florian Krammer; Gene S Tan; Natalie Pica; Dirk Eggink; Jad Maamary; Irina Margine; Randy A Albrecht; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

7.  A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains.

Authors:  Rong Hai; Adolfo García-Sastre; David E Swayne; Peter Palese
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

8.  Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Authors:  Felix Broecker; Sean T H Liu; Weina Sun; Florian Krammer; Viviana Simon; Peter Palese
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

9.  Lamprey VLRB response to influenza virus supports universal rules of immunogenicity and antigenicity.

Authors:  Meghan O Altman; Jack R Bennink; Jonathan W Yewdell; Brantley R Herrin
Journal:  Elife       Date:  2015-08-07       Impact factor: 8.140

10.  The influenza virus hemagglutinin head evolves faster than the stalk domain.

Authors:  Ericka Kirkpatrick; Xueting Qiu; Patrick C Wilson; Justin Bahl; Florian Krammer
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

View more
  4 in total

1.  An In Vitro Microneutralization Assay for Influenza Virus Serology.

Authors:  Frans Cuevas; Hisaaki Kawabata; Florian Krammer; Juan Manuel Carreño
Journal:  Curr Protoc       Date:  2022-07

2.  Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.

Authors:  Jennifer Cable; Anthony Fauci; William E Dowling; Stephan Günther; Dennis A Bente; Pragya Dhruv Yadav; Lawrence C Madoff; Lin-Fa Wang; Rahul K Arora; Maria Van Kerkhove; May C Chu; Thomas Jaenisch; Jonathan H Epstein; Simon David William Frost; Daniel G Bausch; Lisa E Hensley; Éric Bergeron; Ioannis Sitaras; Michael D Gunn; Thomas W Geisbert; César Muñoz-Fontela; Florian Krammer; Emmie de Wit; Pontus Nordenfelt; Erica Ollmann Saphire; Sarah C Gilbert; Kizzmekia S Corbett; Luis M Branco; Sylvain Baize; Neeltje van Doremalen; Marco A Krieger; Sue Ann Costa Clemens; Renske Hesselink; Dan Hartman
Journal:  Ann N Y Acad Sci       Date:  2022-10-02       Impact factor: 6.499

Review 3.  Influenza immune escape under heterogeneous host immune histories.

Authors:  Rachel J Oidtman; Philip Arevalo; Qifang Bi; Lauren McGough; Christopher Joel Russo; Diana Vera Cruz; Marcos Costa Vieira; Katelyn M Gostic
Journal:  Trends Microbiol       Date:  2021-07-01       Impact factor: 17.079

4.  Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases.

Authors:  Marcos C Vieira; Celeste M Donato; Philip Arevalo; Guus F Rimmelzwaan; Timothy Wood; Liza Lopez; Q Sue Huang; Vijaykrishna Dhanasekaran; Katia Koelle; Sarah Cobey
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.